ORLANDO, Fla., April 5, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced at the 102nd Annual Meeting of the American Association for Cancer Research results from 2 studies on the development of antibody-SN-38 conjugates for targeted drug therapy of cancer.
